NEW YORK, February 8, 2017 /PRNewswire/ --
On Tuesday, the NASDAQ Composite ended the day at 5,674.22, up 0.19%; the Dow Jones Industrial Average edged 0.19% higher, to finish at 20,090.29; and the S&P 500 closed at 2,293.08, gaining slightly by 0.02%. However, US markets left a mixed taste at yesterday's closing bell as four sectors ended in positive, four sectors finished the day in negative, and one sector closed flat. Stock-Callers.com has initiated research reports on the following Biotech stocks: Cerulean Pharma Inc. (NASDAQ: CERU), AveXis Inc. (NASDAQ: AVXS), TG Therapeutics Inc. (NASDAQ: TGTX), and Aralez Pharmaceuticals Inc. (NASDAQ: ARLZ). Learn more about these stocks by downloading their comprehensive and free reports at:
On Tuesday, shares in Waltham, Massachusetts-based Cerulean Pharma Inc. ended the session 4.13% lower at $1.16 with a total volume of 2.47 million shares traded. Cerulean Pharma's shares have rallied 41.46% in the last one month and 75.57% in the previous three months. The stock is trading 45.37% above its 50-day moving average. Moreover, shares of the Company, which develops nanotechnology-based therapeutics in the areas of oncology and other diseases in the US, have a Relative Strength Index (RSI) of 69.78. CERU complete research report is just a click away and free at:
Bannockburn, Illinois headquartered AveXis Inc.'s stock finished Tuesday's session 2.71% lower at $57.35 with a total volume of 228,947 shares traded. AveXis' shares have advanced 3.69% in the last one month. The Company's shares are trading above its 50-day and 200-day moving averages by 7.41% and 29.11%, respectively. Shares of AveXis, which engages in developing and commercializing novel treatments for patients suffering from rare and life-threatening neurological genetic diseases, have an RSI of 58.73. The complimentary report on AVXS can be downloaded at:
On Tuesday, shares in New York headquartered TG Therapeutics Inc. recorded a trading volume of 163,319 shares. The stock ended the day 1.02% lower at $4.85. The Company is trading below its 50-day and 200-day moving averages by 2.00% and 23.76%, respectively. Furthermore, shares of TG Therapeutics, which focuses on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases primarily in the US, have an RSI of 51.70. Sign up for your complimentary research report on TGTX at:
Milton, Canada headquartered Aralez Pharmaceuticals Inc.'s stock dropped 1.19%, to close the day at $4.14. The stock recorded a trading volume of 529,440 shares. Aralez Pharma's shares have gained 8.09% in the last three months. The Company's shares are trading 9.89% and 5.70% below its 50-day and 200-day moving averages, respectively. Additionally, shares of the Company, which engages in acquiring, developing, and commercializing products primarily in cardiovascular disease, pain/inflammation, and dermatology areas; and gastrointestinal, women's health, and other nonprescription products, have an RSI of 39.79. Get free access to your research report on ARLZ at:
Stock Callers (SC) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. SC has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
SC has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email email@example.com. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by SC. SC is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
SC, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. SC, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, SC, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither SC nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit
For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:
Phone number: +44 330 808 3765
Office Address: Clyde Offices, Second Floor, 48 West George Street, Glasgow, U.K. -G2 1BP
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Chelmsford Park SA